• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Myomo Inc. (Amendment)

    6/4/24 4:02:07 PM ET
    $MYO
    Industrial Specialties
    Health Care
    Get the next $MYO alert in real time by email
    SC 13G/A 1 p64248sc13ga2.htm AMENDMENT NO. 2

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

     

    Myomo, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.0001
    (Title of Class of Securities)
     
    62857J102
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       
     

     

    SCHEDULE 13G

     

    CUSIP No. 62857J102

     

    1

    Names of Reporting Persons

     

    Triple Gate Partners, LP
    2

    Check the appropriate box if a member of a Group (see instructions)

      

    (a)  o
    (b)  x Reporting Person is affiliated with other persons
    3

    Sec Use Only

      

     
    4

    Citizenship or Place of Organization

      

    Delaware

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With: 

    5

    Sole Voting Power

      

    2,825,344
    6

    Shared Voting Power

      

    0
    7

    Sole Dispositive Power

     

    2,825,344
    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,825,344
    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    o
    11

    Percent of class represented by amount in row (9)

     

    9.81% (see Item 4 below)
    12

    Type of Reporting Person (See Instructions)

     

    PN

     

     Page 2 of 7 
     

     

    CUSIP No. 62857J102

     

    1

    Names of Reporting Persons

     

    Triple Gate Capital, LP
    2

    Check the appropriate box if a member of a Group (see instructions)

     

    (a)  ¨
    (b)  x Reporting Person is affiliated with other persons
    3

    Sec Use Only

     

     
    4

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With: 

    5

    Sole Voting Power

     

    2,825,344 (1)
    6

    Shared Voting Power

     

    0
    7

    Sole Dispositive Power

     

    2,825,344 (1)
    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,825,344 (1)
    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    o
    11

    Percent of class represented by amount in row (9)

     

    9.81% (see Item 4 below)
    12

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1) Triple Gate Capital, LP holds an indirect beneficial interest in the shares which are directly beneficially owned by Triple Gate Partners, LP.

     

     Page 3 of 7 
     

     

    CUSIP No. 62857J102

     

    1

    Names of Reporting Persons

     

    Triple Gate Capital GP, LLC
    2

    Check the appropriate box if a member of a Group (see instructions)

     

    (a)  ¨
    (b)  x Reporting Person is affiliated with other persons
    3

    Sec Use Only

     

     
    4

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With:

    5

    Sole Voting Power

     

    2,825,344 (1)
    6

    Shared Voting Power

     

    0
    7

    Sole Dispositive Power

     

    2,825,344 (1)
    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,825,344 (1)
    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    o
    11

    Percent of class represented by amount in row (9)

     

    9.81% (see Item 4 below)
    12

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1) Triple Gate Capital GP, LLC holds an indirect beneficial interest in the shares which are directly beneficially owned by Triple Gate Partners, LP.

     

     Page 4 of 7 
     

     

    CUSIP No. 62857J102

     

    1

    Names of Reporting Persons

     

    Norbert Gottesman
    2

    Check the appropriate box if a member of a Group (see instructions)

     

    (a)  ¨
    (b)  x Reporting Person is affiliated with other persons
    3

    Sec Use Only

     

     
    4

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With:

    5

    Sole Voting Power

     

    2,825,344 (1)
    6

    Shared Voting Power

     

    0
    7

    Sole Dispositive Power

      

    2,825,344 (1)
    8

    Shared Dispositive Power

      

    0

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,825,344 (1)
    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

      

    o
    11

    Percent of class represented by amount in row (9)

      

    9.81% (see Item 4 below)
    12

    Type of Reporting Person (See Instructions)

      

    IN

     

    (1) Mr. Gottesman may be deemed to hold an indirect beneficial interest in the shares, which are directly beneficially owned by Triple Gate Partners, LP because he is the manager of Triple Gate Capital GP, LLC which is the general partner of Triple Gate Partners, LP. Mr. Gottesman disclaims any beneficial ownership of the shares of Common Stock covered by this Schedule 13G in which he does not have a pecuniary interest.

     

     Page 5 of 7 
     

     

    This Amendment is filed with respect to the shares of common stock, $0.0001 par value (the “Shares”) of Myomo, Inc. (“Issuer”) beneficially owned by the Reporting Persons as of June 4, 2024 and amends and supplements the Schedule 13G filed on August 10, 2020, as previously amended (collectively, the “Schedule 13G”). Except as set forth herein, the Schedule 13G is unmodified.

     

    The names of the persons filing this statement on this Schedule 13G (collectively, the “Reporting Persons”) are Triple Gate Partners, LP (“Partners”), Triple Gate Capital, LP (“IM”), Triple Gate Capital GP, LLC (“GP”), and Mr. Norbert Gottesman. GP is the general partner of Partners. Mr. Gottesman is the manager of GP.

     

    Item 4. Ownership

     

    Item 4 is amended to add the following:

     

    (a) Amount beneficially owned by all Reporting Persons: 2,825,344 Shares

     

    (b) Percent of Class: 9.81% of outstanding Shares, calculated based on 28,814,637 Shares reported as being outstanding as of May 3, 2024 in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on May 8, 2024.

     

    (c)Number of Shares to which the Reporting Persons have:

     

    (i) Sole power to vote or direct the vote: 2,825,344 Shares

     

    (ii) Shared power to vote or direct the vote: 0 Shares

     

    (iii) Sole power to dispose or to direct the disposition of: 2,825,344 Shares

     

    (iv) Shared power to dispose or direct the disposition of: 0 Shares

     

    Item 10.Certifications.

     

    By signing below, the undersigned certifies to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 6 of 7 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  June 4, 2024

     

      TRIPLE GATE PARTNERS, LP
      By: Triple Gate Capital GP, LLC, as General Partner
       
        By: /s/ Norbert Gottesman
          Norbert Gottesman, Manager

     

     

      TRIPLE GATE CAPITAL, LP
      By: Triple Gate Management, LLC, as General Partner
       
        By: /s/ Norbert Gottesman
          Norbert Gottesman, Manager

     

     

      TRIPLE GATE CAPITAL GP, LLC
       
        By: /s/ Norbert Gottesman
          Norbert Gottesman, Manager

     

     

      /s/ Norbert Gottesman
      Norbert Gottesman, Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

      

     

    Page 7 of 7

     

     

     

    Get the next $MYO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYO

    DatePrice TargetRatingAnalyst
    7/31/2024$7.00Buy
    Craig Hallum
    5/20/2024$7.00Buy
    Lake Street
    12/15/2023$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $MYO
    Leadership Updates

    Live Leadership Updates

    See more
    • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

      2/3/25 4:00:00 PM ET
      $INGN
      $MDT
      $MYO
      Industrial Specialties
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Myomo Appoints Heather Getz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

      3/28/24 4:05:00 PM ET
      $BFLY
      $MYO
      Medical Electronics
      Health Care
      Industrial Specialties
    • Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research

      1/30/23 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      10/18/24 2:21:35 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      7/12/24 10:35:49 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      7/11/24 6:02:07 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Commercial Officer Mitchell Micah sold $247,565 worth of shares (48,000 units at $5.16), decreasing direct ownership by 25% to 140,269 units (SEC Form 4)

      4/A - MYOMO, INC. (0001369290) (Issuer)

      3/21/25 4:15:53 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Director Kirk Thomas F bought $37,000 worth of shares (7,400 units at $5.00), increasing direct ownership by 3% to 255,933 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 9:00:08 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: Chief Commercial Officer Mitchell Micah sold $247,565 worth of shares (48,000 units at $5.16), decreasing direct ownership by 25% to 140,572 units (SEC Form 4)

      4/A - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 5:45:37 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Financials

    Live finance-specific insights

    See more
    • Myomo Reports First Quarter 2025 Financial and Operating Results

      Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

      5/7/25 5:11:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Report First Quarter 2025 Financial Results on May 7

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

      4/30/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million

      Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline Introduces 2025 revenue guidance of $50 million to $53 million Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024. Financial and operating highlights for the fourth quarter of 2024 include the following (all comparisons are with the fourth quarter of

      3/10/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Myomo with a new price target

      Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

      7/31/24 7:20:07 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Lake Street initiated coverage on Myomo with a new price target

      Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

      5/20/24 9:00:38 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • H.C. Wainwright initiated coverage on Myomo with a new price target

      H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50

      12/15/23 8:26:14 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kirk Thomas F bought $37,000 worth of shares (7,400 units at $5.00), increasing direct ownership by 3% to 255,933 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 9:00:08 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Kirk Thomas F bought $175,000 worth of shares (50,000 units at $3.50), increasing direct ownership by 27% to 236,499 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      5/31/24 5:43:26 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Kirk Thomas F bought $175,000 worth of shares (50,000 units at $3.50), increasing direct ownership by 37% to 186,499 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/18/24 7:48:52 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myomo Reports First Quarter 2025 Financial and Operating Results

      Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

      5/7/25 5:11:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Host Investor & Analyst Day Event on June 18, 2025

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the Company will be hosting its first-ever Investor & Analyst Day event on Wednesday, June 18, 2025. The event will take place at Myomo's new corporate headquarters and manufacturing facility in Burlington, Mass., and will offer an in-depth look at the Company's latest innovations, strategic plans and growth initiatives to empower individuals with neuromuscular disorders through cutting-edge wearable medical robotics. Institutional investors, shareholders and analysts are invited to reg

      5/1/25 8:30:00 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Report First Quarter 2025 Financial Results on May 7

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

      4/30/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Myomo Inc.

      10-Q - MYOMO, INC. (0001369290) (Filer)

      5/7/25 4:15:23 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MYOMO, INC. (0001369290) (Filer)

      5/7/25 4:10:10 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • SEC Form DEFA14A filed by Myomo Inc.

      DEFA14A - MYOMO, INC. (0001369290) (Filer)

      4/25/25 8:35:25 AM ET
      $MYO
      Industrial Specialties
      Health Care